8-K: Horizon Space Acquisition II Corp. to Merge with SL Bio Ltd., Valuing Combined Entity at $5.568 Billion

Horizon Space Acquisition II Corp. (HSPT) and SL Bio Ltd. have announced a definitive business combination agreement, setting the stage for SL Science Holding Limited (PubCo) to list on Nasdaq with a valuation of $5.568 billion.

Summary

• Horizon Space Acquisition II Corp. (HSPT) and SL Bio Ltd. have entered into a definitive business combination agreement.
• The deal will result in SL Science Holding Limited (PubCo) listing on Nasdaq.
• The implied valuation of the combined entity is $5.568 billion.
• The transaction involves a merger of HSPT with a subsidiary of PubCo, followed by a merger of SL Bio with another subsidiary of PubCo.
• HSPTs shareholders and SL Bios shareholders will receive PubCo ordinary shares as consideration.
• The closing is expected by late 2025, subject to regulatory and shareholder approvals.
• SL Bio is focused on developing cellular and gene therapies for skin care and cancer recovery.
• Key figures in the combined company will include William Wang as CEO and Chairman, Johnson Lau as CFO, and Dr. Ethan Shen as CTO.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the business combination, highlighting the potential for growth and innovation in cancer care and regenerative medicine. The management comments are optimistic and confident in the future of the combined company.

Positives

• The business combination provides SL Bio with access to public markets and capital to scale its operations.
• SL Bio's innovative cellular and gene therapies have the potential to transform cancer treatment and regenerative medicine.
• The combined company will have a strong leadership team with expertise in translational medicine, immunotherapy, and biomanufacturing.
• Listing on Nasdaq will enhance SL Bio's visibility and attract world-class partners.
• The lock-up agreement provides stability by restricting transfer of shares.

Negatives

• The transaction is subject to regulatory and shareholder approvals, and may not close by the expected timeline or at all.
• The combined company's success depends on the ability to successfully develop and commercialize SL Bio's products.
• The market for cellular and gene therapies is competitive and rapidly evolving.
• The lock-up agreement restricts transfer of shares.

Risks

• Failure to obtain regulatory and shareholder approvals.
• Inability to meet Nasdaq listing standards.
• Delays in closing the transaction.
• Failure to realize the anticipated benefits of the business combination.
• Inability to successfully develop and commercialize SL Bio's products.
• Increased competition in the cellular and gene therapy market.
• Potential need to raise additional capital in the future.
• The number of Acquiror Shareholders who exercise their Acquiror Shareholder Redemption Right, the number of Dissenting Acquiror Shares or the failure to obtain Acquiror Shareholders Approval.

Future Outlook

The combined company aims to scale SL Bio's innovations globally, attract world-class partners, and deliver life-changing therapies to patients in need. They plan to make next-generation cellular therapies affordable, off-the-shelf, and available worldwide.

Management Comments

• Mingyu Michael Li, Chief Executive Officer and Chairman of HSPT: 'We are thrilled to announce that HSPT has signed a merger agreement with SL Bio. The achievements demonstrated by SL Bio in the field of cellular therapy align perfectly with our vision to redefine the future of healthcare.'
• William Wang, Chief Executive Officer and Chairman of SL Bio: 'This business combination with HSPT marks a transformative moment for SL Bio and our mission to redefine what is possible in cancer care and regenerative medicine.'

Industry Context

The announcement reflects the ongoing trend of SPAC mergers within the biotechnology and pharmaceutical sectors, as companies seek alternative routes to public listing and access to capital. The focus on cellular and gene therapies aligns with the growing interest in innovative treatments for cancer and regenerative medicine.

Comparison to Industry Standards

• The $5.568 billion valuation is substantial compared to other recent SPAC mergers in the biotech space, suggesting high expectations for SL Bio's technology and pipeline.
• Comparable companies in the cell and gene therapy field, such as CRISPR Therapeutics, bluebird bio, and Kite Pharma (acquired by Gilead), have achieved significant market capitalizations, indicating the potential for substantial growth in this sector.
• The focus on scalability and cost-effectiveness aligns with the industry's need to make these advanced therapies more accessible to a wider patient population.

Stakeholder Impact

• Shareholders of HSPT and SL Bio will receive PubCo ordinary shares.
• Patients may benefit from the development and commercialization of new cellular and gene therapies.
• Employees of SL Bio will become part of the combined company.
• The combined company will seek to attract world-class partners and investors.

Next Steps

• HSPT and SL Bio will file a registration statement on Form F-4 with the SEC.
• HSPT will mail a definitive proxy statement to its shareholders.
• HSPT and SL Bio will seek regulatory and shareholder approvals.
• The Proposed Transactions are expected to close by late 2025.

Key Dates

Keywords

business combination, SL Bio, Horizon Space Acquisition II Corp, SPAC, Merger, cellular therapy, gene therapy, Nasdaq, PubCo, biomedical